News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Bayer AG Seeks EU Approval for New Blood Thinner, Rivaroxaban
January 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AP -- Germany's Bayer AG says it has submitted an application seeking authorization to sell its new anti-clotting drug Rivaroxaban within the European Union.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Vaccines
After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’
April 24, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ for Delaying Stomach Drug
April 24, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Guessing Game: Former HHS Workers’ Next Stops Unclear
April 24, 2025
·
5 min read
·
Angela Gabriel
Drug pricing
Trump Wants To Bring Back International Drug Pricing Policy:
Reuters
April 23, 2025
·
2 min read
·
Annalee Armstrong
